Multiple Endocrine Neoplasia Type 2A (MEN2A)
What is Multiple Endocrine Neoplasia Type 2A (MEN2A)?
Multiple Endocrine Neoplasia Type 2A is a rare inherited condition that causes tumors to grow in several hormone-producing glands. These glands are part of your endocrine system, which controls important body functions through chemical messengers called hormones. MEN2A is caused by changes in a specific gene that gets passed from parent to child.
People with MEN2A typically develop medullary thyroid cancer, a type of cancer that starts in thyroid cells that make the hormone calcitonin. They may also develop tumors in the adrenal glands, which sit on top of your kidneys and make stress hormones. About 20 to 30 percent of people with MEN2A also develop parathyroid problems. The parathyroid glands help control calcium levels in your blood.
MEN2A is different from other forms of cancer because it follows a predictable pattern. Knowing you carry the gene means you can start monitoring and treatment early, often before symptoms appear. This proactive approach can prevent serious complications and improve long-term outcomes.
Symptoms
- A lump or nodule in the neck from thyroid tumors
- Difficulty swallowing or breathing if thyroid growth presses on nearby structures
- Hoarseness or voice changes from thyroid cancer
- High blood pressure episodes with rapid heartbeat from adrenal tumors
- Severe headaches during blood pressure spikes
- Excessive sweating and anxiety attacks
- Kidney stones from elevated calcium levels
- Bone pain or weakness when parathyroid glands are affected
- Fatigue and muscle weakness
- Diarrhea in some cases of medullary thyroid cancer
Many people with MEN2A have no symptoms in the early stages. This is especially true if they are diagnosed through genetic testing before tumors develop. Regular monitoring is essential even when you feel perfectly healthy.
Concerned about Multiple Endocrine Neoplasia Type 2A (MEN2A)? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
MEN2A is caused by inherited mutations in the RET gene. This gene normally helps control cell growth and division. When the RET gene has certain changes, it causes cells in hormone-producing glands to grow out of control and form tumors. The condition follows an autosomal dominant pattern, which means you only need one changed copy of the gene to develop the condition.
If one parent has MEN2A, each child has a 50 percent chance of inheriting the condition. However, about 25 percent of cases occur in people with no family history due to new genetic mutations. Risk factors are primarily genetic rather than lifestyle-related. The age when symptoms appear varies widely, but most people develop medullary thyroid cancer by age 40 if not treated preventively.
How it's diagnosed
MEN2A is diagnosed through genetic testing that looks for mutations in the RET gene. If you have a family history of MEN2A or medullary thyroid cancer, genetic testing is recommended early in childhood. Once a mutation is confirmed, regular monitoring begins to catch any tumors before they cause problems.
Blood tests play a key role in monitoring MEN2A. Parathyroid Hormone testing helps detect parathyroid problems that can occur in about 20 to 30 percent of people with MEN2A. Elevated PTH levels may indicate parathyroid hyperplasia, which causes high calcium in your blood. Rite Aid offers PTH testing as an add-on to help you monitor this condition. Additional testing includes calcitonin levels for thyroid monitoring and tests for adrenal function. Your doctor will create a personalized surveillance plan based on your specific genetic mutation.
Treatment options
- Preventive thyroid surgery, often recommended in childhood to remove the thyroid before cancer develops
- Surgery to remove adrenal tumors called pheochromocytomas when detected
- Parathyroid surgery if hyperplasia causes problematic calcium levels
- Thyroid hormone replacement medication after thyroid removal
- Blood pressure medications before and after adrenal surgery
- Calcium and vitamin D supplements if parathyroid glands are removed
- Regular blood tests to monitor hormone levels and tumor markers
- Genetic counseling for family planning and testing family members
- Annual or more frequent imaging to check for new tumor growth
- Working with an endocrinologist who specializes in genetic endocrine conditions
Need testing for Multiple Endocrine Neoplasia Type 2A (MEN2A)? Add it to your panel.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
MEN2A is one of several multiple endocrine neoplasia syndromes, each caused by different genetic mutations. MEN2A primarily affects the thyroid, adrenal glands, and sometimes parathyroid glands. MEN1 affects different glands including parathyroid, pancreas, and pituitary. MEN2B is similar to MEN2A but tends to be more severe with earlier onset and additional features like distinctive facial appearance.
Genetic testing for MEN2A should be done in early childhood, ideally before age 5, if there is a family history of the condition. Early testing allows for preventive treatment before medullary thyroid cancer develops. If a parent has MEN2A, all children should be tested. Testing can even be done in infancy when there is a known family mutation.
MEN2A itself cannot be cured because it is a genetic condition. However, preventive thyroid surgery before cancer develops can prevent medullary thyroid cancer entirely. Early detection and treatment of adrenal and parathyroid tumors also lead to very good outcomes. With proper monitoring and treatment, most people with MEN2A live normal lifespans.
Blood test frequency depends on your treatment status and age. If you still have your thyroid, you may need calcitonin testing annually or more often. Parathyroid hormone testing is typically done annually to check for parathyroid hyperplasia. After thyroid removal, you will need regular thyroid hormone level checks to ensure your replacement medication dose is correct.
Elevated parathyroid hormone in MEN2A usually indicates parathyroid hyperplasia, where the parathyroid glands become overactive. This causes high calcium levels in your blood, which can lead to kidney stones, bone weakness, and other problems. About 20 to 30 percent of people with MEN2A develop this complication. Treatment may include surgery to remove overactive parathyroid glands.
Preventive thyroid surgery is strongly recommended for most people with MEN2A because the risk of developing medullary thyroid cancer is very high. The timing depends on the specific RET mutation you carry, as some mutations are more aggressive than others. Your doctor will discuss the best timing based on your genetic test results and family history.
Lifestyle changes cannot prevent or cure MEN2A since it is genetic. However, maintaining good overall health supports your body through surgeries and treatments. Eating a balanced diet, staying physically active, and managing stress are important. After thyroid removal, you will need to take thyroid hormone medication daily and maintain regular follow-up appointments.
Pheochromocytomas are tumors of the adrenal glands that make too much adrenaline and related hormones. About 50 percent of people with MEN2A develop these tumors. They cause episodes of very high blood pressure, rapid heartbeat, headaches, and sweating. These tumors are typically benign but must be surgically removed because the hormone excess can be dangerous.
Yes, all first-degree relatives, including parents, siblings, and children, should consider genetic testing if you have MEN2A. Each child of someone with MEN2A has a 50 percent chance of inheriting the condition. Early identification allows for preventive treatment and monitoring. Genetic counseling can help your family understand testing options and implications.
Without treatment, MEN2A almost always leads to medullary thyroid cancer, which can spread to other parts of the body. Untreated pheochromocytomas can cause life-threatening blood pressure crises. Parathyroid problems can damage kidneys and bones over time. This is why early diagnosis through genetic testing and preventive treatment are so important for good long-term outcomes.